A scoping review of 52 studies reveals a bidirectional relationship: gum disease bacteria produce enzymes that degrade GLP-1, while GLP-1 drugs show anti-inflammatory and bone-protective effects in periodontal models.
Bacteria produce DPP-4-like enzymesP. gingivalis and other gum disease bacteria can degrade GLP-1, potentially undermining diabetes drug effectiveness in patients with periodontitis
What the researchers found
Across 52 studies (1990–2025), the review identified several key findings: (1) Periodontitis may impair GLP-1 signaling and worsen glucotoxicity and lipotoxicity in diabetes/obesity. (2) Periodontopathic bacteria, notably P. gingivalis, produce DPP-4-like enzymes that degrade GLP-1 and potentially disrupt glucose regulation. (3) GLP-1 RAs (liraglutide, exendin-4) demonstrated anti-inflammatory, osteoprotective, and regenerative effects in preclinical periodontal models. (4) Host and microbial DPP-4 activity serves as a key mechanistic link between periodontal inflammation and systemic insulin resistance.
Why it matters
About half of adults have some form of gum disease, and the connection between oral health and diabetes is well-established but poorly understood mechanistically. The discovery that oral bacteria can directly degrade GLP-1 provides a concrete molecular link. For the hundreds of millions taking GLP-1 drugs for diabetes, knowing these drugs may also protect their gums adds value, while understanding that gum disease may undermine their effectiveness highlights the importance of oral health.
How the study worked
Scoping review with systematic search of PubMed, Embase, and Cochrane Library for studies published between 1990 and 2025. Fifty-two studies were included, spanning in vitro, animal, and human clinical/observational research examining the relationship between periodontitis and GLP-1 pathways.
What this study cannot tell us
This is a scoping review, which maps the available evidence but doesn't formally assess study quality or pool results. Most GLP-1 periodontal data come from preclinical models rather than human clinical trials. The microbial DPP-4 hypothesis is mechanistically compelling but not yet clinically validated. The heterogeneity of included studies (in vitro to clinical) limits direct comparisons.
How to read the evidence
This is a scoping review synthesizing 52 studies across multiple levels of evidence (in vitro through clinical). While comprehensive in mapping the field, the evidence for the bidirectional relationship is still largely preclinical and mechanistic rather than established through clinical trials.
When this study was published
Published in 2025, this is a timely review as GLP-1 drug prescriptions are surging worldwide and the oral-systemic health connection receives increasing research attention.
The bigger picture
The oral-systemic health connection is one of medicine's most important emerging paradigms. This review adds a specific molecular mechanism — microbial DPP-4-mediated GLP-1 degradation — to the known links between gum disease and metabolic disorders. As GLP-1 drugs become some of the most prescribed medications worldwide, understanding how oral health affects their efficacy and vice versa has enormous clinical implications.
Questions still open
- Could treating gum disease improve GLP-1 drug effectiveness in diabetes patients by reducing microbial DPP-4 activity?
- Should patients on GLP-1 drugs receive more aggressive periodontal treatment to maximize both oral and metabolic benefits?
- Could locally administered GLP-1 drugs or DPP-4 inhibitors be developed specifically for periodontal therapy?
Common questions
How can mouth bacteria affect a diabetes drug?
Should I tell my dentist I'm taking a GLP-1 drug like Ozempic?
Read the original research
Periodontitis and GLP-1 pathways: a new frontier in oral-systemic health connections -a scoping review.
Frontiers in clinical diabetes and healthcare, 6, 1679511
Citation
Jeong, Natalie; Chuang, Lin-Hsin; Ho, Yolanda. (2025). Periodontitis and GLP-1 pathways: a new frontier in oral-systemic health connections -a scoping review.. Frontiers in clinical diabetes and healthcare, 6, 1679511. https://doi.org/10.3389/fcdhc.2025.1679511